Your browser doesn't support javascript.
loading
Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound.
Ertl, Iris E; Lemberger, Ursula; Ilijazi, Dafina; Hassler, Melanie R; Bruchbacher, Andreas; Brettner, Robert; Kronabitter, Hannah; Gutmann, Michael; Vician, Petra; Zeitler, Gerhard; Koren, Anna; Lardeau, Charles-Hugues; Mohr, Thomas; Haitel, Andrea; Compérat, Eva; Oszwald, André; Wasinger, Gabriel; Clozel, Thomas; Elemento, Olivier; Kubicek, Stefan; Berger, Walter; Shariat, Shahrokh F.
Afiliação
  • Ertl IE; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Lemberger U; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Ilijazi D; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Hassler MR; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Bruchbacher A; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Brettner R; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Kronabitter H; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Gutmann M; Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.
  • Vician P; Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.
  • Zeitler G; Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.
  • Koren A; CeMM Research Center for Molecular Medicine, Vienna, Austria.
  • Lardeau CH; CeMM Research Center for Molecular Medicine, Vienna, Austria.
  • Mohr T; Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.
  • Haitel A; Department of Pathology, Medical University of Vienna, Vienna, Austria.
  • Compérat E; Department of Pathology, Medical University of Vienna, Vienna, Austria.
  • Oszwald A; Department of Pathology, Medical University of Vienna, Vienna, Austria.
  • Wasinger G; Department of Pathology, Medical University of Vienna, Vienna, Austria.
  • Clozel T; OWKIN, New York City, NY, USA; Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY, USA.
  • Elemento O; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA; Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY, USA; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
  • Kubicek S; CeMM Research Center for Molecular Medicine, Vienna, Austria.
  • Berger W; Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria. Electronic address: walter.berger@meduniwien.ac.at.
  • Shariat SF; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Cha
Eur Urol ; 82(3): 261-270, 2022 09.
Article em En | MEDLINE | ID: mdl-35393162

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article